-

HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases. Dr. Chen will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.

“We are very pleased to welcome Jin to the HighTide team,” said Liping Liu, Ph.D., Chief Executive Officer of HighTide. “Her expertise in clinical pharmacology and familiarity with our indications of interest are an excellent fit for HighTide’s global efforts to develop HTD1801 and expand our pipeline for patients with unmet needs.”

Prior to joining HighTide, Dr. Chen served various roles at Novartis from 2006-2021, including Clinical Development Director and Director, Clinical Pharmacology where she contributed to multiple IND submissions and an NDA submission and approval. Prior to Novartis, Dr. Chen served as Clinical PK Scientist at Amgen. Dr. Chen earned a Ph.D. in pharmaceutical sciences from the University at Buffalo, the State University of New York.

About HighTide Therapeutics

HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The lead drug candidate, HTD1801, is a first-in-class new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), nonalcoholic steatohepatitis comorbid with type 2 diabetes mellitus (NASH + T2DM), T2DM comorbid with nonalcoholic fatty liver disease (T2DM + NAFLD), etc.

For additional information, please visit https://hightidetx.com.

Contacts

Jeffrey Dao
ir@hightidetx.com
+1-650-580-3872

Industry:

HighTide Therapeutics Inc.

Release Summary
Jin Chen Appointed SVP DMP & Clinical Pharmacology
Release Versions
English

Contacts

Jeffrey Dao
ir@hightidetx.com
+1-650-580-3872

More News From HighTide Therapeutics Inc.

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 – 8, 2022). A poster presentation titled “Effects of HTD1801 on t...

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development. Mr. Ripley has 25 years of experience in pharmaceutical business development. Most recently he served as Head of Global Business Development for Alpha Biopharma. Mr. Ripley will report to D...

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China. Led by Professor Linong Ji, Director of the D...
Back to Newsroom